Cloverfields Capital Group’s Pfizer PFE Stock Holding History

Cloverfields Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-80	Closed	-$3K	–	69
2021 Q2	$3K	Buy	+80	New	+$3.11K	﹤0.01%	66

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Cloverfields Capital Group's PFE Position: Q3 2021 in Review

Cloverfields Capital Group sold out of Pfizer (PFE) in Q3 2021, closing a stake of 80 shares — an estimated $3K sold.

Cloverfields Capital Group first reported a position in PFE in Q2 2021 and held it in 1 quarter. The position peaked at $3K in Q2 2021. 2,803 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Cloverfields Capital Group reported no remaining Pfizer position as of Q3 2021 after selling out during the quarter.
Cloverfields Capital Group sold 80 Pfizer shares in Q3 2021, an estimated $3K.
Cloverfields Capital Group first reported a position in Pfizer in Q2 2021 and held it in 1 quarter.
Cloverfields Capital Group's Pfizer position peaked at $3K in Q2 2021.
2,803 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Cloverfields Capital Group's 13F filing for Q3 2021, filed 12 Nov 2021.